Trial · NCT07016321

Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)

NCT07016321, Phase 2, Phase 3, Recruiting, Johns Hopkins University

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative). Trials, record NCT07016321. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07016321

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)
NCT number: NCT07016321
Status: Recruiting
Phases: Phase 2, Phase 3
Enrollment: 600 participants, estimated
Lead sponsor: Johns Hopkins University
Conditions: Dengue
Interventions: Emetine Hydrochloride 6mg, Placebo, Emetine Hydrochloride 12mg
First posted: 2025-06-11
Last updated: 2026-10-13

Source ClinicalTrials.gov

Registered outcomes15

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Evaluate effectiveness of emetine in dengue patients assessed by 28-day mortality or progression	28 days	28-day mortality or progression to severe dengue, defined as severe plasma leakage, severe bleeding, or severe organ involvement (death and severe dengue will be assessed as a composite outcome)
Primary	Safety of emetine assessed by number of adverse events	Up to 28 days	Record serious adverse events and toxicities by organ-system
Primary	Safety of emetine assessed by rate of drug discontinuation	Up to 28 days	Evaluate the safety of emetine assessed by rate of drug discontinuation
Secondary	Recovery (≥ 3 days without symptoms)	Up to 14 days	Sustained resolution of all dengue symptoms for ≥ 3 consecutive days (where the first of those days is considered the date of recovery)
Secondary	Time to Virologic Clearance of Dengue Virus by Qualitative RT-PCR	Pre-dose (day 0), day 3, and day 5	Time to test negativity that is longitudinally measured by Qualitative real-time polymerase chain reaction (RT-PCR).
Secondary	Quantitative Viral Load Assessment by RT-PCR Cycle Threshold (Ct) Values	Days 0,3, 5	Measures of the average RT-PCR cycle threshold (Ct) values for dengue virus RNA at specified time points post-randomization.
Secondary	Changes in inflammatory marker measured by hematocrit	Days 0 to 5	Measure hematocrit in percentage (%) for patients
Secondary	Changes in inflammatory marker measured by white blood count	Day 0-5	Measure white blood count (WBC) for patients measured per microliter (mcL)
Secondary	Changes in inflammatory marker measured by reticulocyte count	Day 0-5	Measure reticulocyte count as percentage (%) for patients
Secondary	Changes in inflammatory marker measured by platelet count	Day 0-5	Measure platelet count for patients measured per microliter (mcL)

1 to 10 of 15Source ClinicalTrials.gov

See all 15 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers8

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
4347870	BACKGROUND	PubMed
16591432	BACKGROUND	PubMed
27322111	BACKGROUND	PubMed
27534439	BACKGROUND	PubMed
32251767	BACKGROUND	PubMed
33124646	BACKGROUND	PubMed
33261173	BACKGROUND	PubMed
35680407	BACKGROUND	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07016321

GET https://conductscience.org/api/trials/v1/NCT07016321/registered

API reference For AI assistants